Skip to main content
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: Curr Oncol Rep. 2019 May 7;21(7):56. doi: 10.1007/s11912-019-0806-2

Table 2.

All-Grade Immune Checkpoint Inhibitor Immune Related Adverse Events

All-Grade ICI irAEs (% overall occurrence in major trials according to manufacturers’ prescribing information)
Cardiovascular Pulmonary Gastrointestinal Endocrine Genitourinary Nervous/Ophthalmic Integumentary/Musculoskeletal
PD-1 Inhibitors Nivolumab Myocarditis (<1%)
Pericarditis (<1%)
Vasculitis (<1%)		 Pneumonitis (3.1%) Colitis (2.9%)
Hepatitis (1.8%)
Pancreatitis (<1%)
Gastritis (<1%)
Duodenitis (<1%)		 Hypothyroidism (9%)
Hyperthyroidism (2.7%)
Hypopituitarism (<1%)
Adrenal Insufficiency (1%)
T1DM (<1%)		 Nephritis (1.2%) Encephalitis (<1%)
CN Paresis (<1%)
Demyelination (<1%)
Neuropathy (<1%)
GBS (<1%)
Uveitis (<1%)
Iritis (<1%)		 Rash/Dermatitis (9%)
Rhabdomyolysis (<1%)
Myositis (<1%)
Polymyalgia Rheumatica (<1%)
Sarcoidosis (<1%)
Pembrolizumab Myocarditis (<1%)
Vasculitis (<1%)		 Pneumonitis (3.4%) Colitis (1.7%)
Hepatitis (<1%)
Pancreatitis (<1%)		 Hypothyroidism (8.5%)
Hyperthyroidism (3.4%)
Hypopituitarism (<1%)
T1DM (<1%)		 Nephritis (<1%) Encephalitis (<1%)
Uveitis (<1%)
GBS (<1%)
Myelitis (<1%)		 Arthritis (1.5%)
Myositis (<1%)
Sarcoidosis (<1%)
Rash/Dermatitis (unknown %)
PD-L1 Inhibitors Atezolizumab Myocarditis (<1%)
Vasculitis (<1%)		 Pneumonitis (2.5%) Colitis (20%)
Hepatitis (9%)
Pancreatitis (<1%)		 Hypothyroidism (4.6%)
Hyperthyroidism (1.6%)
Adrenal Insufficiency (<1%)
T1DM (<1%)
Hypophysitis (<1%)		 Nephritis (<1%) Encephalitis (<1%)
CN Paresis (<1%)
Demyelination (<1%)
Neuropathy (<1%)
GBS (<1%)
Uveitis (<1%)
Iritis (<1%)		 Rash/Dermatitis (<1%)
Rhabdomyolysis (<1%)
Myositis (<1%)
Polymyalgia Rheumatica (<1%)
Avelumab Myocarditis (<1%) Pneumonitis (1.2%) Colitis (1.5%)
Hepatitis (<1%)		 Hypothyroidism (5%)
Hyperthyroidism (<1%)
Adrenal Insufficiency (<1%)
T1DM (<1%)
Hypopituitarism (<1%)		 Nephritis (<1%) GBS (<1%)
Uveitis (<1%)		 Rash/Dermatitis (<1%)
Myositis (<1%)
Arthritis (<1%)
Durvalumab Myocarditis (<1%) Pneumonitis (5%) Colitis (18%)
Hepatitis (12%)		 Hypothyroidism (11%)
Hyperthyroidism (7%)
Adrenal Insufficiency (<1%)
T1DM (<1%)
Hypopituitarism (<1%)		 Nephritis (6.3%) Meningitis (<1%)
Uveitis (<1%)		 Rash/Dermatitis (26%)
Myositis (<1%)
CTLA-4 Inhibitor Ipilimumab Colitis (12-30%)
Hepatitis (4.5-16%)		 Endocrinopathies (4.1-28%) Neuropathy (<1-2.5%) Rash/Dermatitis (14.5-25%)
Combination Regimens Ipilimumab + Nivolumab Myocarditis (<1%)
Pericarditis (<1%)
Vasculitis (<1%)		 Pneumonitis (1.7-6%) Colitis (7-26%)
Hepatitis (7-13%)
Pancreatitis (<1%)
Gastritis (<1%)
Duodenitis (<1%)		 Hypothyroidism (15-22%)
Hyperthyroidism (8-12%)
Hypophysitis (3.4-9%)
Adrenal Insufficiency (5-7%)
T1DM (1.5-2.7%)
Hypopituitarism (<1%)		 Nephritis (1.7-4.6%) Encephalitis (<1%)
CN Paresis (<1%)
Demyelination (<1%)
Neuropathy (<1%)
GBS (<1%)
Uveitis (<1%)
Iritis (<1%)		 Rash/Dermatitis (14-22.6%)
Rhabdomyolysis (<1%)
Myositis (<1%)
Polymyalgia Rheumatica (<1%)
Sarcoidosis (<1%)

T1DM: Type 1 Diabetes Mellitus, CN: Cranial Nerve, GBS: Guillain-Barre Syndrome